Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Anti-CLL1 CAR-T cell therapy in pediatric R/R AML

Rayne Rouce • 27 May 2021
ASCO 2021
Acute Myeloid Leukemia Leukemia CAR-T

Rayne H Rouce, MD, Baylor College of Medicine, Houston, TX & Texas Children’s Hospital, Houston, TX, provides a summary of the Phase I trial (ChiCTR1900027684) of an anti-CLL1 2nd generation chimeric antigen receptor (CAR) T-cell therapy in pediatric patients with relapsed/refractory acute myeloid leukemia (AML). Whilst CAR T-cell therapy has been successful in treating B-cell malignancies, CAR T-cell-based leukemia treatment in AML are limited due to disease heterogeneity. In a cohort of 11 patients, 10 completely responded to treatment, demonstrating efficacy and safety. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from Rayne Rouce

8:27
Anti CD7 CAR T-cell therapy in T-ALL
Rayne Rouce • 27 May 2021
0:49
The future of pediatric clinical trials
Rayne Rouce • 27 May 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals